GlassScriptPhysician profile
Kendall Berry Byrd
NPI 1477103141
$3,187.98
in general payments reported to CMS, 2019-2025
31 companies · $713 in 2025
The $713 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $551 · 2022: $855 · 2023: $619 · 2024: $449 · 2025: $713.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,782.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,781.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $479.25 | 2021-2025 | |
| Mayne Pharma Commercial LLC | $375.34 | 2021-2025 | |
| Astellas Pharma US INC | $251.30 | 2022-2025 | Veozah |
| Avion Pharmaceuticals | $234.29 | 2022 | |
| Exeltis, USA INC. | $214.66 | 2021-2025 | Tyblume, Slynd |
| Biogen, INC. | $200.77 | 2024-2025 | Zurzuvae, Vumerity |
| Sumitomo Pharma America, INC. | $181.49 | 2023-2025 | Myfembree |
| Daiichi Sankyo INC. | $179.11 | 2021-2023 | Injectafer |
| Organon LLC | $164.31 | 2021-2025 | Nexplanon, Nuvaring |
| Bayer Healthcare Pharmaceuticals INC. | $121.21 | 2022-2025 | |
| Millicent US INC | $102.38 | 2021-2025 | Femlyv |
| Shield Therapeutics INC | $87.61 | 2023-2024 | Accrufer |
| Hologic Sales and Service, LLC | $67.32 | 2025 | Aptima, Myosure Tissue Removal Device |
| Agile Therapeutics, INC. | $64.95 | 2021-2022 | |
| Aspira Women'S Health INC | $64.03 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $57.31 | 2024-2025 | |
| Lupin INC. | $34.69 | 2021 | |
| Nevro Corp. | $34.68 | 2022 | |
| Therapeuticsmd, INC. | $33.23 | 2021 | |
| Exact Sciences Corporation | $28.81 | 2025 | Cologuard Collection Kit |
| Mimedx Group, INC. | $28.33 | 2024 | |
| Medicem INC. | $23.77 | 2022 | |
| Molnlycke Health Care US, LLC | $20.93 | 2025 | Mepilex Border Post-Op Ag, Avance |
| Takeda Pharmaceuticals U.S.A., INC. | $19.42 | 2021 | |
| Minerva Surgical, INC | $19.37 | 2024 | |
| Mylan Pharmaceuticals INC. | $18.81 | 2021 | |
| Ethicon US, LLC | $18.48 | 2022 | |
| Myovant Sciences INC. | $18.21 | 2021 | |
| Merck Sharp & Dohme LLC | $17.15 | 2024 | Gardasil 9, Gardasil |
| Coopersurgical, INC. | $14.11 | 2022 | |
| Ibsa Pharma INC. | $12.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kendall Byrd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.